On October 15, 2025, China’s National Medical Products Administration (NMPA) announced the cancellation of 80 drug registration certificates, including well-known products such as loratadine tablets.

The resurgence of COVID-19 in China has presented challenges to our mental health under lockdown and made grit more important than ever to help us get through difficult times.

Each year since 1950, people around the world have marked April 7 as World Health Day.

Entrepreneurial orientation (i.e., the extent to which a business entity embraces product innovation, market entry, and risk-taking) is a crucial yardstick by which investors assess the future prospects of any given company.

Although COVID-19 has placed the life sciences and healthcare (LSH) industry under great stress, it has also served as a valuable reminder that a healthy life is one of the primary goals of society. At the same time, however, the pandemic has also placed leadership (and the skills required to lead) in the sector back in the spotlight.

The COVID-19 epidemic will drive the proliferation of new technologies and models in the pharmaceutical industry. In the short term, the majority of pharmaceutical companies will be slightly affected as demand is exploding for treatment drugs, protective gear and test reagents related to the epidemic. In the long run, however, the outbreak may profoundly affect the pharmaceutical industry.